From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: AVO

Search articles by EPIC code

Advanced Oncotherapy – New Record Low But How Bad Will It Get?

Paid for researcher Hardman may keep on telling mug punters that AIM-listed Advanced Oncotherapy (AVO) is a great company with a target price of gazillions, but the reality is that this cash-guzzling outfit which keeps on failing to deliver any income, is running out of funding options as the price crashes ever lower. Just how bad could it get?

Advanced Oncotherapy: It Is Surely In Real Trouble Now, the Fat Lady awaits

It seems that no amount of ramping can help AIM-listed Advanced Oncotherapy (AVO) now. The company is in deep shit – and has essentially admitted as much. I would suggest also that the recent note from pay-as-you-go “researcher” (to be polite) Hardman is also an almighty sell signal. At the root of the problem is the cash-guzzling nature of the business, but with a 25p par price and the shares now at just 7.5p it is clear that shareholders are about to take a bath. Or the whole shooting match could follow fellow proton therapy outfit Rutherford Health (RUTH - ex-of the Aquis lobster pot) to the great central bank in the sky. Anyone holding is, in my view, insane.

Advanced Oncotherapy – is the funding farce about to end, prompting a share price collapse? This company could well go bust!

Each month, Advanced Oncotherapy (AVO) needs between £1 million and £2 million to keep the lights on. And to date, each month Odey Asset Management has been writing a cheque, buying shares at 25p (par value) to keep the show on the road. But the shares are slipping and is this farce about to end prompting a share price collapse?

Advanced Oncotherapy – Worth 156p, Hardman? You’re ‘Avin’ A Giraffe

Paid-for investment "research" prostitute Hardman has released an update on AIM-listed Advanced Oncotherapy (AVO). This means that 1) the company is desperate for cash (no surprises there!), 2) a placing is on the way and 3) that Crispin Odey is sweating over his multiple purchases at a premium at 25p per share when the shares were trading below the 25p par price, given that they are now worth just 11.25p per share. I have much time for Odey, but he has surely called this one spectacularly wrong on multiple occasions.

Advanced Oncotherapy – Don’t Be Fooled By Today’s Pathetic Ramparoonie

We all know AIM-listed Advanced Oncotherapy (AVO) faces a funding crisis: it was sending around £2.6 million every month to the great central bank in the sky during the last reporting period, the interims to June 2022, when it had just £2.5 million of cash left over. Worse still, only a fool (step forward Crispin Odey?) would pay the par price of 25p for equity trading in the market now at just 12.25p. So without a capital reorganisation, the company is truly skewered.

Letter to the FCA – Odey Asset Management wasting clients cash?

I have commented extensively on this issue. I cannot understand how Odey is not both creating a false market in shares in Advanced Oncotherapy (AVO) – so inflating its AUM - but also knowingly and deliberately losing money for clients. I have written to the FCA asking it to examine the matter

Request that you investigate Odey Asset Management over share dealings in Advanced Oncotherapy

Advanced Oncotherapy – Scraping The Barrel - what is Crispin Odey doing with his client's cash?: SELL

AIM-listed Advanced Oncotherapy (AVO) has announced that it has raised another £1.5 million from an existing institutional investor at 25p per share, the par price below which the law prevents the issue of confetti. With the stock having closed last week at just 16.75p, this is surely pure madness on the part of that institutional investor – who we are reliably told is none other than Crispin Odey. How his compliance officer is allowing this, heaven only knows.
Page 1 of 27 (266 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments